MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- BIOCON
BIOCON Share Price 
(BICN)
Here is the latest stock price and chart of Biocon Ltd. For more details, see the Biocon Ltd company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jun 19, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)251.00 | Open (Rs) 244.05 | High (Rs) 252.50 | Low (Rs) 242.80 |
| % Change3.25 | Volume 184,294 | Value (Rs) 45,698,913 | 52-Week H/L 359.18 / 238.90 |
| Live NSE Quotes | Jun 19, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)250.95 | Open (Rs) 244.20 | High (Rs) 252.50 | Low (Rs) 242.70 |
| % Change3.19 | Volume 4,023,193 | Value (Rs) 997,138,690 | 52-Week H/L 359.00 / 239.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 13.63 | P/E Ratio (x) 18.42 | Market Cap (Rs m) 150,600.00 | P/BV (x) 2.91 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
BIOCON Share Price Today:
BIOCON last traded price was up 3.3% to Rs 251.0 on the BSE. On the NSE, BIOCON last traded price was up 3.2% to Rs 251.0. The total volume of shares traded was 4.2 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.3%. And the benchmark S&P BSE SENSEX was at 39,112.7 (up 0.2%).
Over the last 30 days, the BIOCON share price is down 4.3%. And over the last one year, BIOCON share price is down 17.6%.
|
| |
Today's Market
Sensex Ends 66 Points Higher; Realty and Consumer Durable Stocks Witness Buying(Closing)
Indian share markets continued to witness volatility during closing hours and ended their day on a flat note.
Related Views On News
BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)
Apr 26, 2019 | Updated on Apr 26, 2019For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)
Jun 6, 2019Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...
Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)
Jun 12, 2019This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.
Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)
Jun 10, 2019The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.
MoreTRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON 8-QTR ANALYSIS
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.